摘要
Abstract
Objective To detect the CDK5RAP2 expression in breast cancer before neoadjuvant chemotherapy (NAC),and analyze its value in evaluating the effect of NAC. Methods 191 patients with primary invasive breast in Department of Breast Surgery,Tianjin Medical University Cancer Institute and Hospital in 2014 were selected. The clinical and pathological data were collected,including age,family history of cancer,menopausal status,tumor diameter,lymph node metastasis,clinical stage,and molecular type. Breast cancer tissue specimens were needle aspirated and the expression of CDK5RAP2 was determined by immunohistochemistry. After 6 cycles of TEC NAC,patients accepted radical mastectomy or breast - conserving surgery. The chemotherapy effect was preoperatively evaluated. Results In patients,18 cases(9. 4% ) got pCR,23 cases(12. 1% )got cCR,106 cases(55. 5% )got PR and 44 cases(23. 0% )got SD. There were statistically significant difference in the efficacy of NAC among patients with different tumor diameter and molecular type( P < 0. 05). CDK5RAP2 expression was negative in 38 patients(19. 9% )and positive in 153 patients(80. 1% ). There was statistically significant difference in the efficacy of NAC among patients between different CDK5RAP2 expression(P < 0. 05). There were no statistically significant difference in the efficacy of NAC between different CDK5RAP2 expression among Luminal A,basal - like breast cancer patients( P > 0. 05). There were statistically significant difference in the efficacy of NAC between different CDK5RAP2 expression among Luminal B,Her-2 positive breast cancer patients(P < 0. 05). Conclusion The expression of CDK5RAP2 could predict the efficacy of NAC in breast cancer,especially in Luminal B and Her-2 positive breast cancer.关键词
乳腺肿瘤/细胞周期蛋白依赖激酶 5/新辅助化疗/治疗结果Key words
Breast neoplasms/Cyclin - dependent kinase 5/Neoadjuvant chemotherapy/Treatment outcome分类
医药卫生
